Author Archives: Simon

MonTa announces completion of phase I does-escalation

MonTa announces completion of our phase I dose-escalation study with completion of the last cohort [...]

MonTa Biosciences Granted Broad U.S. Patent for Lead Immunotherapy Drug MBS8

We are pleased to announce that MonTa Biosciences has been granted a key U.S. patent [...]

MBS8 preclinical data published in prestigious Journal of Immunology

MonTa shares publication of MBS8 and how our TLR7 agonist demonstrates superior anti tumor activity [...]

MonTa Biosciences Secures Key Patents in Israel, China, and Japan for MBS8

We are proud to announce that MonTa Biosciences has been granted patents in Israel, China, [...]